Literature DB >> 11992549

Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer.

Kazuya Kudoh1, Yoshihito Ichikawa, Sadao Yoshida, Misako Hirai, Yoshihiro Kikuchi, Ichiro Nagata, Masanao Miwa, Kazuhiko Uchida.   

Abstract

To define the involvement of p16/CDKN2 and p15/MTS2 tumor-suppressor genes for response to chemotherapy in primary epithelial ovarian cancer, we analyzed alterations of the gene in 45 patients who were treated with primary cytoreductive surgery followed by 6 courses of cis-diamminedichloroplatinum (II) (cisplatin)-based combination chemotherapy. Homozygous deletion of p16/CDKN2 and p15/MTS2 genes was found in 8 (18%) and 15 (33%) cases, respectively. Response to the chemotherapy was confirmed by finding at second surgery after the chemotherapy in 26 patients, resulting in 17 responders and 9 nonresponders. The abundance of gene deletion in nonresponders (56%) was significantly higher (p = 0.0463) when compared to that in responders (18%). Moreover, the deletion of genes was a significant poor prognostic factor (p = 0.0441) in advanced ovarian cancer. These results suggest that deletion of p16/CDKN2 and/or p15/MTS2 is a potential indicator for poor chemotherapy response and adverse prognosis in ovarian cancer patients. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11992549     DOI： 10.1002/ijc.10331

Source DB:  PubMed          Journal:  Int J Cancer        ISSN： 0020-7136            Impact factor:   7.396


  15 in total

1.  Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.

Authors:  Gottfried E Konecny; Boris Winterhoff; Teodora Kolarova; Jingwei Qi; Kanthinh Manivong; Judy Dering; Guorong Yang; Meenal Chalukya; He-Jing Wang; Lee Anderson; Kimberly R Kalli; Richard S Finn; Charles Ginther; Siân Jones; Victor E Velculescu; Darren Riehle; William A Cliby; Sophia Randolph; Maria Koehler; Lynn C Hartmann; Dennis J Slamon
Journal:  Clin Cancer Res       Date:  2011-01-28       Impact factor: 12.531

Review 2.  Role of p53 and Rb in ovarian cancer.

Authors:  David C Corney; Andrea Flesken-Nikitin; Jinhyang Choi; Alexander Yu Nikitin
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

Review 3.  Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies.

Authors:  Linjuan Xu; Jing Cai; Qiang Yang; Hui Ding; Liying Wu; Tao Li; Zehua Wang
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-18       Impact factor: 4.553

4.  p16 Protein and gigaxonin are associated with the ubiquitination of NFκB in cisplatin-induced senescence of cancer cells.

Authors:  Mysore S Veena; Reason Wilken; Jun-Ying Zheng; Ankur Gholkar; Natarajan Venkatesan; Darshni Vira; Sameer Ahmed; Saroj K Basak; Clifton L Dalgard; Sandhiya Ravichandran; Raj K Batra; Noriyuki Kasahara; David Elashoff; Michael C Fishbein; Julian P Whitelegge; Jorge Z Torres; Marilene B Wang; Eri S Srivatsan
Journal:  J Biol Chem       Date:  2014-10-20       Impact factor: 5.157

5.  p16INK4A positivity in benign, premalignant and malignant cervical glandular lesions: a potential diagnostic problem.

Authors:  N Murphy; C C B B Heffron; B King; U G Ganuguapati; M Ring; E McGuinness; O Sheils; J J O'Leary
Journal:  Virchows Arch       Date:  2004-09-18       Impact factor: 4.064

6.  Consortium analysis of 7 candidate SNPs for ovarian cancer.

Authors:  Susan J Ramus; Robert A Vierkant; Sharon E Johnatty; Malcolm C Pike; David J Van Den Berg; Anna H Wu; Celeste Leigh Pearce; Usha Menon; Aleksandra Gentry-Maharaj; Simon A Gayther; Richard A DiCioccio; Valerie McGuire; Alice S Whittemore; Honglin Song; Douglas F Easton; Paul D P Pharoah; Montserrat Garcia-Closas; Stephen Chanock; Jolanta Lissowska; Louise Brinton; Kathryn L Terry; Daniel W Cramer; Shelley S Tworoger; Susan E Hankinson; Andrew Berchuck; Patricia G Moorman; Joellen M Schildkraut; Julie M Cunningham; Mark Liebow; Susanne Krüger Kjaer; Estrid Hogdall; Claus Hogdall; Jan Blaakaer; Roberta B Ness; Kirsten B Moysich; Robert P Edwards; Michael E Carney; Galina Lurie; Marc T Goodman; Shan Wang-Gohrke; Silke Kropp; Jenny Chang-Claude; Penelope M Webb; Xiaoqing Chen; Jonathan Beesley; Georgia Chenevix-Trench; Ellen L Goode
Journal:  Int J Cancer       Date:  2008-07-15       Impact factor: 7.396

7.  Candidate gene analysis using imputed genotypes: cell cycle single-nucleotide polymorphisms and ovarian cancer risk.

Authors:  Ellen L Goode; Brooke L Fridley; Robert A Vierkant; Julie M Cunningham; Catherine M Phelan; Stephanie Anderson; David N Rider; Kristin L White; V Shane Pankratz; Honglin Song; Estrid Hogdall; Susanne K Kjaer; Alice S Whittemore; Richard DiCioccio; Susan J Ramus; Simon A Gayther; Joellen M Schildkraut; Paul P D Pharaoh; Thomas A Sellers
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-03-03       Impact factor: 4.254

8.  Long noncoding RNA LINC01296 plays an oncogenic role in colorectal cancer by suppressing p15 expression.

Authors:  Jianing Xu; Zhehao Zhang; Dong Shen; Ting Zhang; Jinsong Zhang; Wei De
Journal:  J Int Med Res       Date:  2021-05       Impact factor: 1.671

Review 9.  Tumour suppressor genes in chemotherapeutic drug response.

Authors:  Dulcie Lai; Stacy Visser-Grieve; Xiaolong Yang
Journal:  Biosci Rep       Date:  2012-08       Impact factor: 3.840

10.  Expression of p15INK⁴b and p57KIP² and relationship with clinicopathological features and prognosis in patients with vulvar squamous cell carcinoma.

Authors:  Ruth Holm; Mette Førsund; Mai T Nguyen; Jahn M Nesland; Claes G Trope
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.